RNA Drug Pioneer RiboBio Passes Hong Kong IPO Hearing with $2B+ Partnership Portfolio
核心洞察
Suzhou RiboBio (搜索) successfully passed its Hong Kong Stock Exchange listing hearing, marking the official launch of its IPO for the leading Chinese RNA drug developer.
The company reported 56.6% revenue growth to 103.8 million yuan ($14.7 million) in H1 2025, while narrowing losses from 141.6 million yuan to 97.8 million yuan year-over-year.
RiboBio (搜索) operates one of the world's largest siRNA pipelines with seven clinical-stage candidates, including four in Phase 2 trials targeting cardiovascular, metabolic, renal and liver diseases (搜索).
Suzhou RiboBio Life Science Co. Ltd. (搜索) has successfully passed its listing hearing for the Hong Kong Stock Exchange, officially launching its initial public offering as one of China's leading RNA drug developers. The company's post-hearing information pack, released on the exchange's website, marks a significant milestone for the specialized siRNA therapeutics developer.
Strong Financial Performance Drives IPO Launch
RiboBio (搜索) demonstrated robust financial growth in its latest prospectus, with revenue rising 56.6% to 103.8 million yuan ($14.7 million) in the first six months of 2025, compared to 66.3 million yuan in the same period the previous year. Simultaneously, the company's losses narrowed significantly from 141.6 million yuan to 97.8 million yuan year-over-year, indicating improved operational efficiency.
The Suzhou-based company, founded in 2007, has established itself as a pioneer in RNA-based nucleotide drug development, specializing in small interfering RNA (siRNA) therapies that block gene actions responsible for various diseases.
Expansive Clinical Pipeline Positions Company as Global Leader
RiboBio (搜索) currently operates one of the world's largest siRNA pipelines, featuring seven clinical-stage candidate drugs targeting cardiovascular, metabolic, renal and liver diseases (搜索). Four of these candidates have already advanced to Phase 2 clinical trials, demonstrating the company's clinical development capabilities.
The company's core product RBD4059, an siRNA targeting FXI (搜索), represents the world's first and most advanced siRNA drug in clinical development for treating thrombotic diseases (搜索). Patient enrollment for the Phase 2a clinical trial was completed in February 2025, with trial completion expected by the end of 2025.
Additional promising candidates include RBD5044, an siRNA targeting APOC3 for treating hypertriglyceridemia (搜索), which is the second siRNA globally to enter clinical development for this target. The drug is currently undergoing Phase 2 trials in Sweden for patients with mixed dyslipidemia. RBD7022, targeting PCSK9 for hypercholesterolemia (搜索) treatment, completed its Phase 1 trial in China in March 2025, with Phase 2 trials being advanced by partner Qilu Pharmaceutical.
Strategic Partnerships Validate Technology Platform
RiboBio (搜索) has secured significant licensing agreements with major pharmaceutical companies, validating its technological capabilities and market potential. The company struck a licensing deal with China Qilu Pharmaceutical (搜索), granting rights to manufacture and sell RiboBio's high cholesterol drug in Mainland China, Hong Kong and Macao.
Most notably, Germany's Boehringer Ingelheim has agreed to jointly develop hepatitis (搜索) therapies with RiboBio (搜索) in a collaboration valued at more than $2 billion. These partnerships have contributed to the company's recent revenue growth, with milestone payments triggered in the first half of 2025.
Proprietary Delivery Technology Creates Competitive Moat
RiboBio (搜索) has developed proprietary GalNAc delivery technology, positioning itself among the few companies globally with self-developed and clinically validated delivery systems for siRNA drugs. The company's liver-targeting RiboGalSTAR delivery technology serves as the foundation for many pipeline assets, addressing the critical challenge of efficient and specific siRNA delivery.
Beyond hepatic targeting, RiboBio (搜索) has advanced extrahepatic delivery capabilities through its RiboPepSTAR platform for kidneys, central nervous system, adipose tissues, and muscles, as well as the RiboOncoSTAR platform for oncology applications.
Market Opportunity Reflects Industry Growth Trajectory
The global oligonucleotide market is projected to reach $54.9 billion by 2034, growing at an average annual rate of 29.4% between 2024 and 2029, according to research cited in the company's prospectus. SiRNA drugs currently account for approximately 44.5% of the market in 2024.
According to Frost & Sullivan data referenced in company materials, the global small nucleic acid therapy market is expected to reach $18.6 billion by 2029, with a compound annual growth rate of 29.5% from 2024 to 2029.
Clinical Milestones and Regulatory Recognition
RiboBio (搜索)'s product RBD1016 targeting HDV (搜索) received orphan drug designation from the European Medicines Agency in October 2025, providing regulatory validation for the company's development programs. Beyond its clinical pipeline, the company maintains over 20 preclinical projects planned for advancement into clinical development.
The company's IPO launch, with CICC (搜索) and Citi (搜索) serving as joint sponsors, represents a significant opportunity for investors to participate in China's small nucleic acid drug innovation sector, as the industry experiences what experts consider the "third wave" of pharmaceutical development following small molecule drugs and antibody therapeutics.